AMIODARONE HYDROCHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

amiodarone hydrochloride injection, solution

remedyrepack inc. - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (vf) and hemodynamically unstable ventricular tachycardia (vt) in patients refractory to other therapy. amiodarone also can be used to treat patients with vt/vf for whom oral amiodarone is indicated, but who are unable to take oral medication. during or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy [see dosage and administration ( 2)] . use amiodarone for acute treatment until the patient's ventricular arrhythmias are stabilized. most patients will require this therapy for 48 to 96 hours, but amiodarone may be safely administered for longer periods if necessary. amiodarone is contraindicated in patients with: - known hypersensitivity to any of the components of amiodarone injection, including iodine. hypersensitivity reactions may involve rash, angioedema, cutaneous/mucosal hemorrhage (bleeding), fever, arthralgias (joint pains), eosinophilia (abnormal blood counts), urticaria (hives), thrombotic thrombocytopenic purpura, or severe periarteritis (inflammation around blood vessels). - cardiogenic shock. - marked sinus bradycardia. - second- or third-degree atrio-ventricular (av) block unless a functioning pacemaker is available. pregnancy category d [see warnings and precautions ( 5.8)] . teratogenic effects amiodarone and desethylamiodarone cross the placenta. reported risks include: - neonatal bradycardia, qt prolongation, and periodic ventricular extrasystoles - neonatal hypothyroidism (with or without goiter) detected antenatally or in the newborn and reported even after a few days of exposure - neonatal hyperthyroxinemia - neurodevelopmental abnormalities independent of thyroid function, including speech delay and difficulties with written language and arithmetic, delayed motor development, and ataxia. - jerk nystagmus with synchronous head titubation - fetal growth retardation - premature birth amiodarone has caused a variety of adverse effects in animals. amiodarone was given intravenously to rabbits at dosages of 5, 10, or 25 mg/kg per day (about 0.1, 0.3, and 0.7 times the human intravenous maintenance dose of 0.5 mg/min on a body surface area basis), during gestation days 8 to 16 (organogenesis). the incidence of maternal deaths increased with increasing dose and occurred in all treated groups, and controls. mean fetal weights were significantly decreased in the low and middle dose groups and embryotoxicity (as manifested by fewer full- term fetuses and increased resorptions) occurred at dosages of 10 mg/kg and above. there were no significant differences in the number of minor fetal abnormalities and no major fetal abnormalities were observed. amiodarone was administered by continuous intravenous infusion to rats at dosages of 25, 50, or 100 mg/kg per day (about 0.3, 0.7, and 1.3 times the human intravenous maintenance dose of 0.5 mg/min on a body surface area basis) during gestation days 8 to 16 (organogenesis). maternal toxicity (manifest as reduced weight gain and food consumption) and embryotoxicity (manifest as increased resorptions, decreased live litter size and fetal body weights, and delayed sternal and metacarpal ossification) were observed in the 100 mg/kg group. the delayed ossification was reversible and related to decreased fetal weight. fetal thyroid tissues appeared normal in all groups. nonteratogenic effects very high concentrations of amiodarone and desethylamiodarone may be found in testes. elevated follicle-stimulating hormone and luteinizing hormone levels, suggestive of testicular dysfunction, have been reported in men on long-term amiodarone treatment. while planning pregnancy after discontinuation of amiodarone treatment, consider the long half-life of amiodarone and its metabolite dea. it is not known whether the use of amiodarone during labor or delivery has any immediate or delayed adverse effects. preclinical studies in rodents have not shown any effect on the duration of gestation or on parturition. amiodarone and one of its major metabolites, desethylamiodarone (dea), are excreted in human milk, suggesting that breast-feeding could expose the nursing infant to a significant dose of the drug. nursing offspring of lactating rats administered amiodarone have demonstrated reduced viability and reduced body weight gains. the risk of exposing the infant to amiodarone must be weighed against the potential benefit of arrhythmia suppression in the mother. advise the mother to discontinue nursing. the safety and effectiveness of amiodarone in pediatric patients have not been established; therefore, the use of amiodarone in pediatric patients is not recommended. in a pediatric trial of 61 patients, aged 30 days to 15 years, hypotension (36%), bradycardia (20%), and av block (15%) were common dose- related adverse reactions and were severe or life-threatening in some cases. injection site reactions were seen in 5 (25%) of the 20 patients receiving intravenous amiodarone through a peripheral vein irrespective of dose regimen. amiodarone injection contains the preservative benzyl alcohol [see description ( 11)] . there have been reports of fatal “gasping syndrome” in neonates (children less than one month of age) following the administration of intravenous solutions containing the preservative benzyl alcohol. symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse. clinical studies of amiodarone did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. carefully consider dose selection in an elderly patient. in general, start at the low end of the dosing range in the elderly to reflect the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.

AMIODARONE HYDROCHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

amiodarone hydrochloride injection, solution

general injectables & vaccines, inc - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (vf) and hemodynamically unstable ventricular tachycardia (vt) in patients refractory to other therapy. amiodarone also can be used to treat patients with vt/vf for whom oral amiodarone is indicated, but who are unable to take oral medication. during or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy [see dosage and administration (2)]. use amiodarone for acute treatment until the patient's ventricular arrhythmias are stabilized. most patients will require this therapy for 48 to 96 hours, but amiodarone may be safely administered for longer periods if necessary. amiodarone is contraindicated in patients with: - known hypersensitivity to any of the components of amiodarone, including iodine. hypersensitivity reactions may involve rash, angioedema, cutaneous/mucosal hemorrhage (bleeding), fever, arthralgias (joint pains), eosinophilia (abnormal bl

MANDOKEF 1 g INJECTION South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

mandokef 1 g injection

pharmacare limited û woodmead - injection - see ingredients - each vial contains cefamandole nafate equivalent to cefamandole 1 g

MANCEF 750 Injection South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

mancef 750 injection

pharmacare limited - injection - each vial contains cefamandole nafate equivalent to cefamandole 750,0 mg

MANCEF 1 000 Injection South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

mancef 1 000 injection

pharmacare limited - injection - each vial contains cefamandole nafate equivalent to cefamandole 1 000,0 mg

PHEBRA CALCIUM GLUCONATE  931 mg/10 mL injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

phebra calcium gluconate 931 mg/10 ml injection vial

phebra pty ltd - calcium gluconate monohydrate, quantity: 931 mg - injection, solution - excipient ingredients: calcium saccharate; water for injections - calcium gluconate is a calcium salt used primarily for the prevention and treatment of calcium deficiency. parenteral administation of calcium gluconate is needed in acute hypocalcaemia and hypocalcsemic tetany. it can be given intravenously in the treatment of severe hyper-kalaemia and in overdosage of magnesium sulphate, as calcium is the antagonist of magnesium toxicity. iv injections have been used in the treatment of acute renal biliary and intestinal colic. calcium has been used as an inotrope in cardiac resuscitation. they may also be used for the prevention of hypocalcaemia in exchange transfusions, and in long term electrolyte replacement therapy.

AMIODARONE HYDROCHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

amiodarone hydrochloride injection, solution

henry schein, inc - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (vf) and hemodynamically unstable ventricular tachycardia (vt) in patients refractory to other therapy. amiodarone also can be used to treat patients with vt/vf for whom oral amiodarone is indicated, but who are unable to take oral medication. during or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy [see dosage and administration (2)]. use amiodarone for acute treatment until the patient's ventricular arrhythmias are stabilized. most patients will require this therapy for 48 to 96 hours, but amiodarone may be safely administered for longer periods if necessary. amiodarone is contraindicated in patients with: - known hypersensitivity to any of the components of amiodarone, including iodine. hypersensitivity reactions may involve rash, angioedema, cutaneous/mucosal hemorrhage (bleeding), fever, arthralgias (joint pains), eosinophilia (abnormal bl

AMIODARONE HYDROCHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

amiodarone hydrochloride injection, solution

medical purchasing solutions, llc - amiodarone hydrochloride (unii: 976728sy6z) (amiodarone - unii:n3rq532iut) - amiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (vf) and hemodynamically unstable ventricular tachycardia (vt) in patients refractory to other therapy. amiodarone also can be used to treat patients with vt/vf for whom oral amiodarone is indicated, but who are unable to take oral medication. during or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy [see dosage and administration ( 2)] . use amiodarone for acute treatment until the patient's ventricular arrhythmias are stabilized. most patients will require this therapy for 48 to 96 hours, but amiodarone may be safely administered for longer periods if necessary. amiodarone is contraindicated in patients with: - known hypersensitivity to any of the components of amiodarone injection, including iodine. hypersensitivity reactions may involve rash, angioedema, cutaneous/mucosal hemorrhage (

Clindamycin-hameln New Zealand - English - Medsafe (Medicines Safety Authority)

clindamycin-hameln

max health limited - clindamycin phosphate 178.23 mg/ml equivalent to clindamycin 150mg/ml - solution for injection - 300 mg/2ml - active: clindamycin phosphate 178.23 mg/ml equivalent to clindamycin 150mg/ml excipient: benzyl alcohol disodium edetate nitrogen sodium hydroxide water for injection - clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.

Clindamycin-hameln New Zealand - English - Medsafe (Medicines Safety Authority)

clindamycin-hameln

max health limited - clindamycin phosphate 178.23 mg/ml equivalent to clindamycin 150mg/ml - solution for injection - 600 mg/4ml - active: clindamycin phosphate 178.23 mg/ml equivalent to clindamycin 150mg/ml excipient: benzyl alcohol disodium edetate nitrogen sodium hydroxide water for injection - clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.